At Geneos Therapeutics, we believe that personalized therapies are the future of cancer treatment. Our approach is to target unique neoantigens (abnormal mutations produced by cancer cells) from individual patient tumors to develop novel treatments for cancer. Geneos Therapeutics technology is designed to identify, design, manufacture, and deliver tumor specific neoantigen-targeted personalized immunotherapies. We have an experienced management team with a track record of success in building immunotherapy-based companies. Geneos holds an exclusive license of Inovio's DNA-based immunotherapy platform, which has demonstrated in multiple clinical trials, animal models, and peer-reviewed publications the ability to elicit a potent and tumor-specific immune response to fight cancer.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/21/19 | $10,500,000 | Series A |
Inovio Sante Ventures  | undisclosed |
